Abraham, Ivo <br/><br/>
Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries.  [electronic resource] 

 -  Future oncology (London, England)  2014 
 - 1599-609 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1744-8301 
<br/><br/><label>Standard No.: </label>10.2217/fon.14.43  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anemia--chemically induced<br/>Antibodies, Monoclonal, Humanized--economics<br/>Antibodies, Monoclonal, Murine-Derived--economics<br/>Antineoplastic Agents--adverse effects<br/>Bevacizumab<br/>Biosimilar Pharmaceuticals--therapeutic use<br/>Drug Costs<br/>Epoetin Alfa<br/>Erythropoietin--economics<br/>European Union<br/>Hematinics--economics<br/>Humans<br/>Models, Economic<br/>Neoplasms--drug therapy<br/>Recombinant Proteins--economics<br/>Rituximab<br/>Trastuzumab